UNSPSC 51282003: Tigecycline

This classification denotes an antibiotic with the molecular formula C29H39N5O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70JE2N95KR, chemically known as 2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-((((1,1-dimethylethyl)amino)acetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4s,4as,5ar,12as)- but generally known as tigecycline, which bears US NIH Compound Identifier 5282044.

UNSPSC 51282003 Tigecycline is a Commodity code covering antibiotic pharmaceuticals that state and local health systems procure through cooperative purchasing agreements and multistate pharmaceutical contracts. State and local governments acquire tigecycline—a broad-spectrum antibiotic used in serious infections—primarily as part of formulary-based bulk purchasing programs that establish pricing and supply arrangements with manufacturers through authorized pharmaceutical wholesalers. The issuing bodies soliciting under this code are state health departments and cooperative purchasing alliances that aggregate demand across multiple state and local facilities, including hospitals, public health agencies, and institutional care settings. Procurement is structured around compliance with FDA requirements, current Good Manufacturing Practices (cGMP), and the Drug Supply Chain Security Act (DSCSA), with vendors required to maintain relationships with established pharmaceutical wholesalers and provide detailed product information including National Drug Codes and pricing across multiple format options.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded products effective July 1, 2026. Evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing stability, and 5 percent each on administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Vendors must carry workers' compensation and commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, with contract terms of two years for new responders and optional extensions at MMCAP's discretion.